Clearmind Medicine Inc. - Common Shares (NQ:CMND)

6.000 +5.290 (+745.07%)

Delayed Quote Updated: 3:59 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

SciSparc And Clearmind Reveal Three Unique Combinations Of Future Psychedelic-Based Compounds ↗

February 22, 2023

SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that as part of its...

Via Benzinga

SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds

February 22, 2023

Clearmind Medicine submitted patent applications to protect the novel compounds

From SciSparc Ltd

Via GlobeNewswire

Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds

February 22, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

Novel Combination Of Cannabis-Like Compound With Classical Psychedelics Searches IP Coverage In US ↗

February 15, 2023

Israeli-based next-gen psychedelics biotech Clearmind Medicine (NASDAQ: CMND) together with partner clinical-stage pharma company SciSparc (NASDAQ: SPRC) has filed three provisional patent applications...

Via Benzinga

SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US

February 15, 2023

From SciSparc Ltd

Via GlobeNewswire

Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US

February 15, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv

February 14, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

February 08, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

EXCLUSIVE: Next-Generation Psychedelics, MEAI - The Road Ahead ↗

February 01, 2023

(Part four of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction

Via Benzinga

Israeli Biotech Develops Ketamine Analogue To Treat Major Depression With Promising Results ↗

January 31, 2023

Israeli-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) and partners Bar-Ilan University and Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center have obtained...

Via Benzinga

Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound

January 31, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More ↗

January 25, 2023

Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First?

Via Benzinga

Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023

January 25, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

January 25, 2023

It's time to start off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday!

Via InvestorPlace

EXCLUSIVE: Next-Generation Psychedelics, MEAI - What And When ↗

January 24, 2023

(Part three of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction

Via Benzinga

EXCLUSIVE: Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains ↗

January 23, 2023

(This is part two of a four-part series) Check out part one in the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction

Via Benzinga

Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction ↗

January 20, 2023

(Part one of a four-part series) Increasing evidence of psychedelics’ potential for benefiting both mental and physical health conditions are moving biotech companies and scientists in the sector to...

Via Benzinga

Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects ↗

January 19, 2023

Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.

Via Benzinga

Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum

January 19, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

Envisioning A Cocaine-Addiction Treatment: This Next-Gen Psychedelic Shows Positive Results ↗

January 18, 2023

Israel-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) shared additional positive results on the impact of the MEAI molecule in the natural reward process in an in-vivo preclinical...

Via Benzinga

Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment

January 17, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

January 10, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

This Original Psychedelic-Based Obesity Treatment Set To First-In-Human Trials ↗

January 06, 2023

Psychedelics biopharma company Clearmind Medicine Inc. (NASDAQ: CMND) and clinical-stage firm SciSparc Ltd.

Via Benzinga

Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

January 05, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

Israel-Based Clearmind Medicine Inc. CEO Discusses the Potential of Psychedelics for Addiction Treatment in Audio Interview with SmallCapVoice.com

January 04, 2023

Via ACCESSWIRE

What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways ↗

January 03, 2023

What a year for psychedelics!

Via Benzinga

Clearmind Medicine Inc.’s Psychedelic-Based Therapeutics Are Revolutionary To The Pharmaceutical Sector; Treating AUD In The Crosshairs ($CMND)

January 03, 2023

Via AB Newswire

Topics Intellectual Property

Clearmind Medicine Inc. Positions To Deliver A First-To-Market Psychedelic-Based Treatment For AUD ($CMND)

December 29, 2022

Via AB Newswire

Topics Intellectual Property

Clearmind Medicine Announces Shareholders Meeting Results

December 29, 2022

From Clearmind Medicine Inc.

Via GlobeNewswire

Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder

December 28, 2022

From Clearmind Medicine Inc.

Via GlobeNewswire

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.